GSK plc (GLAXF)

OTCMKTS · Delayed Price · Currency is USD
18.77
-0.46 (-2.39%)
Oct 29, 2024, 1:44 PM EDT
4.28%
Market Cap 76.98B
Revenue (ttm) 39.74B
Net Income (ttm) 5.10B
Shares Out n/a
EPS (ttm) 1.24
PE Ratio n/a
Forward PE n/a
Dividend 0.38 (1.99%)
Ex-Dividend Date Aug 15, 2024
Volume 164
Open 18.77
Previous Close 19.23
Day's Range 18.77 - 18.77
52-Week Range 16.80 - 23.00
Beta 0.31
Analysts n/a
Price Target n/a
Earnings Date Oct 30, 2024

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]

Sector Healthcare
Founded 1715
Employees 70,212
Stock Exchange OTCMKTS
Ticker Symbol GLAXF
Full Company Profile

Financial Performance

In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.

Financial numbers in GBP Financial Statements

News

Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY

-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for...

1 day ago - PRNewsWire

Haleon: Too Vanilla For My Liking - I See Why GSK & Pfizer Wanted Out

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock and why I recommend a sell rating.

5 days ago - Seeking Alpha

Companies Reporting: McDonalds, Aston Martin, GSK, Next

McDonalds, Aston Martin, GSK, Next are amongst the FTSE 350 and other companies reporting earnings for the week of 28 November

5 days ago - The Armchair Trader

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines fo...

5 days ago - Benzinga

New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

PHILADELPHIA--(BUSINESS WIRE)-- #Adult--New data for AREXVY, GSK's RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.

5 days ago - Business Wire

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

GSK's lawsuit adds uncertainty to Moderna's already declining stock, increasing short-selling activity. Read why I downgrade MRNA from buy to hold.

7 days ago - Seeking Alpha

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

8 days ago - Benzinga

Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors

In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehe...

11 days ago - Benzinga

ViiV reports positive real-world data for HIV prevention drug

ViiV Healthcare, which is co-owned by GSK (GSK) and Pfizer (PFE), said real-world studies showed its drug Apretude was more than 99% effective as a preventive treatment for HIV.

13 days ago - Seeking Alpha

GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement

GSK Plc (NYSE: GSK) has filed a lawsuit against Moderna, Inc. (NASDAQ: MRNA) and its affiliates, alleging that Moderna’s mRNA vaccines infringe on patents developed by GSK . According to GSK, the te...

14 days ago - Benzinga

Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R

Last week, Sanofi SA (NASDAQ: SNY) said it is negotiating with Clayton Dubilier & Rice (CD&R) to potentially sell a 50% controlling stake in Opella, its consumer healthcare business . The deal could ...

14 days ago - Benzinga

GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines

GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.

14 days ago - Reuters

GSK's Depemokimab Shows Positive Trial Results, Boosting Stock

GSK's Depemokimab Shows Positive Trial Results, Boosting Stock

15 days ago - GuruFocus

Stocks to Watch Monday: Tesla, Boeing, MicroStrategy, GSK

16 days ago - The Wall Street Journal

Who will attend the UK investment summit and what is on the agenda?

Guests at all-day event include the NHS boss, execs from Google, BlackRock and Aviva – and Gareth Southgate ‘I’ve faced a lot of challenges’: Poppy Gustafsson on her new role The government will host ...

16 days ago - The Guardian

Doubts on UK Industrial Strategy Cloud Investment Push at Summit

When UK Prime Minister Keir Starmer welcomes business leaders to a major investment summit in London on Monday, his message to executives from the likes of BlackRock, Vodafone and GSK will be simple: ...

17 days ago - BNN Bloomberg

GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain

Earlier this week, GSK plc (NYSE: GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts . These cases account for ...

18 days ago - Benzinga

MARKET REPORT: GSK shares jump as Zantac cancer claims deal reached

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and several rivals into crisis.

18 days ago - This is Money

GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations

In June, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccine...

19 days ago - Benzinga

GSK: The Worst Is Finally Over (Rating Upgrade)

GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable at 12.4x. Explore more details here.

19 days ago - Seeking Alpha